{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-098584","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-09-10T12:10:38+00:00","discovered_at":"2026-09-10T12:15:00.322001+00:00","generated_at":"2026-09-10T12:15:05.277148+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Turn Therapeutics to present at Stifel 2026 Virtual Immunology and Inflammation Forum","bullets":["CEO Bradley Burnam and Dr. Stephen M. Hahn to present on September 23, 2026 at 1:30 PM ET.","Presentation covers atopic dermatitis program, including pruritus-focused stage 2 enrichment strategy.","Emerging findings across patient populations: moderate-severe baseline pruritus and lower EASI with high IGA.","Live webcast on company website; replay available for approximately six months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-098584","json":"https://secwatch.observer/filing/0001213900-26-098584.json","markdown":"https://secwatch.observer/filing/0001213900-26-098584.md","text":"https://secwatch.observer/filing/0001213900-26-098584.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026098584/0001213900-26-098584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026098584/ea0305037-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T12:15:05.277148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}